Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12176858rdf:typepubmed:Citationlld:pubmed
pubmed-article:12176858lifeskim:mentionsumls-concept:C0042210lld:lifeskim
pubmed-article:12176858lifeskim:mentionsumls-concept:C0450254lld:lifeskim
pubmed-article:12176858pubmed:dateCreated2002-8-14lld:pubmed
pubmed-article:12176858pubmed:abstractTextDangerous pathogens are defined by the UK Health and Safety Executive's advisory committee as category 3 (those which cause severe human disease for which prophylaxis or therapy is usually available) or category 4 (as for category 3, but for which prophylaxis or therapy is not available). Research and development of vaccines for such pathogens is challenging, due to the safety constraints in the manipulation of these pathogens. This chapter discusses the various approaches which can be taken to develop candidate vaccines for these pathogens, including the potential impact of genome sequencing on shortening the time required for R&D. For these pathogens, a direct test of the efficacy of the candidate vaccines in man is not ethical and, therefore, particular emphasis is placed on the demonstration of efficacy in animal models. Emphasis is also placed on the derivation of surrogate markers of efficacy and a demonstration that these correlate with protection in the animal model.lld:pubmed
pubmed-article:12176858pubmed:languageenglld:pubmed
pubmed-article:12176858pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12176858pubmed:citationSubsetIMlld:pubmed
pubmed-article:12176858pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12176858pubmed:statusMEDLINElld:pubmed
pubmed-article:12176858pubmed:issn0007-1420lld:pubmed
pubmed-article:12176858pubmed:authorpubmed-author:TitballR WRWlld:pubmed
pubmed-article:12176858pubmed:authorpubmed-author:WilliamsonE...lld:pubmed
pubmed-article:12176858pubmed:issnTypePrintlld:pubmed
pubmed-article:12176858pubmed:volume62lld:pubmed
pubmed-article:12176858pubmed:ownerNLMlld:pubmed
pubmed-article:12176858pubmed:authorsCompleteYlld:pubmed
pubmed-article:12176858pubmed:pagination163-73lld:pubmed
pubmed-article:12176858pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:12176858pubmed:meshHeadingpubmed-meshheading:12176858...lld:pubmed
pubmed-article:12176858pubmed:meshHeadingpubmed-meshheading:12176858...lld:pubmed
pubmed-article:12176858pubmed:meshHeadingpubmed-meshheading:12176858...lld:pubmed
pubmed-article:12176858pubmed:meshHeadingpubmed-meshheading:12176858...lld:pubmed
pubmed-article:12176858pubmed:meshHeadingpubmed-meshheading:12176858...lld:pubmed
pubmed-article:12176858pubmed:meshHeadingpubmed-meshheading:12176858...lld:pubmed
pubmed-article:12176858pubmed:meshHeadingpubmed-meshheading:12176858...lld:pubmed
pubmed-article:12176858pubmed:year2002lld:pubmed
pubmed-article:12176858pubmed:articleTitleVaccines against dangerous pathogens.lld:pubmed
pubmed-article:12176858pubmed:affiliationDSTL, Chemical and Biological Sciences, Porton Down, Salisbury, UK.lld:pubmed
pubmed-article:12176858pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12176858pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12176858lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12176858lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12176858lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12176858lld:pubmed